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1. Introduction 
Pulmonary emphysema is a chronic disease defined pathologically as an abnormal 
permanent destruction and enlargement of air spaces distal to the terminal bronchioles, 
accompanied by the destruction of alveolar walls without predominant fibrosis. 
Emphysema frequently occurs in overlapping association with chronic bronchitis which is 
clinically defined as chronic productive cough for three months in each of two successive 
years in a patient in whom other causes of chronic cough have been excluded. Previously, 
emphysema and chronic bronchitis was regarded as distinct entities and grouped under the 
umbrella term Chronic obstructive pulmonary disease(COPD). 
COPD is a collection of heterogeneous conditions characterized by persistent expiratory 
airflow limitation. There is significant overlap and co-existence of conditions like 
emphysema, chronic bronchitis and asthma(see Figure 1). COPD is heterogeneous clinically 
and at a pathophysiologic level and its recognition, has led to new initiatives to categorize 
and define COPD and its subsets.(American Thoracic Society[ATS],1995,2010;British 
Thoracic Society[BTS],1997) 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) does not emphasise 
on the distinction between emphysema and chronic bronchitis (GOLD,2006). This report 
produced by the National Heart, Lung, and Blood Institute (NHLBI) and the World 
Health Organization(WHO) emphasised on the common feature of altered lung function 
recognizes both the systemic nature and the heterogeneity of COPD and defines it as 
follows: 
“Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
with some significant extrapulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by airflow limitation 
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that is not fully reversible. The airflow limitation is usually progressive and associated 
with an abnormal inflammatory response of the lungs to noxious particles or 
gases."(GOLD,2006) 
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Fig. 1. Schematic Venn diagram of subsets of COPD. This is a non-proportional Venn 
diagram adapted from Am J Respir Care Med (ATS,1995) showing subsets of patients with 
chronic bronchitis, emphysema, and asthma(circles) and their relationship to airflow 
obstruction (box). The subsets comprising COPD are 4,5,6,7,8 and 9. Asthma is depicted by 
subset 3, whose airflow obstruction is completely reversible and are not considered to have 
COPD.  
2. Historical background 
COPD and its various subsets have been known in human history since pre-industrialisation 
era. (Snider, 1992 as cited in Shapiro SD,2010). Badham is known to have first used of the 
term “chronic bronchitis” in 1808(Badham,1808 as cited in Shapiro SD,2010 ). Fletcher and 
Laennec have presented early reviews and studies in 18th and 19th century (Fletcher et 
al.,1976;Laennec,1835 as cited in Shapiro SD,2010). Reid demonstrated  increased mucus 
gland size in his pathologic studies and led to the development of the “Reid Index” and 
highlighted the anatomic basis for chronic bronchitis(Reid,1960). 
Ruysch described enlarged respiratory air spaces on the surface of human lungs in 
1691(Ruysch,1691 as cited in Shapiro SD,2010). Over the next centuries, work of Matthew 
Baillie, Laennec and Gough helped in describing the pathologic enlargement of airspaces 
and classified it between centriacinar emphysema and panacinar 
emphysema(Baillie,1799,1808,Gough,1952;Laennec,1835 as cited in Shapiro SD,2010). 
Various “hypothesis” were proposed over the years to describe the disease pathogenesis: 
i. “Dutch hypothesis” - originated  by Orie(Netherlands) proposed that asthma and 
airway hyperreactivity leads to fixed airflow limitation. (Orie et al.,1961 as cited in 
Shapiro SD,2010) 
ii. “British hypothesis” - suggested the concept that mucus hypersecretion led to airway 
remodeling and airflow limitation.(Fletcher,1976 as cited in Shapiro SD,2010) 
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iii. “Protease-antiprotease hypothesis”(“Swedish hypothesis”) - association of homozygous 
alpha1 protease inhibitor deficiency with emphysema was discovered by Laurell and 
Eriksson in Sweden. (Laurell & Eriksson,1963;Snider et al.,1974 as cited in Shapiro 
SD,2010) 
iv. “American hypothesis” -  American pathologist Averill Liebow emphasised that altered 
repair mechanisms contribute to the development of COPD and that deficient 
maintenance of lung structure, could lead to emphysema.(Liebow,1959;Rennard,2004  
as cited in Shapiro SD,2010) 
COPD has been described and subclassified on various clinical, etiopathogenetic and 
pathological basis. Chronic bronchitis has been associated with a “blue bloater” clinical 
phenotype on basis of the concept that altered airway anatomy would lead to heterogeneity 
of airflow distribution within the lung, resulting in ventilation-perfusion imbalance, 
hypoxemia, and right heart failure. On the other hand, emphysema has been described with 
the “pink puffer” phenotype based on the concept that it primarily causes decreased airflow 
from the obstruction and less prominent hypoxia. 
Pathologic studies delineate inflammation of airway structures (bronchitis) from destruction 
of the alveolar wall (emphysema). Emphysema has been described as centriacinar, 
panacinar and paraseptal based on the location of emphysematous airspaces in an acinus. 
Centriacinar variety is common in cigarette smokers and  panacinar emphysema is 
predominant in proteinase inhibitor deficiency. 
3. Epidemiology 
COPD is a major public health problem with a high and continually increasing morbidity. 
The Burden of Obstructive Lung Disease (BOLD) study showed that the worldwide 
prevalence of COPD (stage II or higher) was 10.1%. This figure varied by geographic 
location and by sex with prevalence among men at 11.8% (8.6-22.2%) and among women at 
8.5% (5.1-16.7%)(Buist et al.,2007). The wide differences  noted was partly due to site and sex 
differences in the prevalence of smoking. The true prevalence is likely higher because COPD 
is both under-recognized and under-diagnosed. COPD was the sixth leading cause of death 
worldwide in 1990 and is expected to become the third leading cause of death by 
2020(Murray & Lopez,1997 as cited in Shapiro SD,2010). 
COPD has higher prevalence in low-socioeconomic population(Fletcher,1976). Commonly, 
patients present in their fifth decade of life with productive cough or acute chest illness. 
Alpha-1 Protease Inhibitor (A1PI) deficient patients present earlier than other COPD 
patients in 3rd-4th decade of life. COPD progresses with age and is more prevalent in elderly 
populations. In the United States, 15% of the total population aged 55 to 64 will have 
moderate COPD (GOLD stage 2, FEV1 < 80% predicted), and this increases to over 25% for 
those older than 75(Stockley et al.,2009 as cited in Shapiro SD,2010). 
3.1 Risk factors 
3.1.1 Cigarette smoking 
Cigarette smoking is the most significant and predictable risk factor in pathogenesis of 
COPD. Almost 80% of individuals who have COPD and 80% who die from COPD in the 
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United States are smokers (Mannino et al.,2002 as cited in Shapiro SD,2010). The estimated 
fraction of COPD mortality attributable to smoking was 54% for men 30–69 years of age and 
52% for men 70 years of age or older (Ezzati & Lopez,2003 as cited in ATS,2010). There is a 
consistent exposure–response relationship which is demonstrated in evidence from cohort 
studies fulfilling the causal criterion of temporality (exposure preceding onset of disease). 
Although only 15% of smokers have clinically significant COPD, smoking leads to a 
predictable dose-dependent loss of lung function in pre-symptomatic phase which 
accelerates with age and has prognostic implications (Rennard & Vestbo,2006 as cited in 
Shapiro SD,2010). Smoking has supra-additive effect in worsening lung function and 
prognosis when combined with other risk factors like A1PI deficiency or occupational 
exposures(Silverman et al.,2009 as cited in Shapiro SD,2010). 
3.1.2 Genetic predilection 
Genetically determined deficiency of alpha1–protease inhibitor (A1PI) represents a proven 
genetic abnormality that predisposes to COPD(Ericksson,1964;Laurell & Eriksson,1963 as 
cited in Shapiro SD,2010). A1PI is inherited by codominant alleles on chromosomal segment 
14q32.1. Early adult-onset emphysema associated with A1PI deficiency occurs most 
commonly with PiZZ (mutation in SERPINA1 gene) phenotype. It is prevalent globally but  
most commonly found in whites of Northern European ancestry. Worldwide there are an 
estimated 116,000,000 carriers and 1,100,000 individuals with severe ǂ1-AT deficiency.(Boas 
& Winnie,2011) 
Linkage analysis studies in early-onset COPD families have identified another serine 
proteinase inhibitor(serpin E2) on chromosome 2 as a potential defect site(DeMeo 
etal.,2006;Wilk et al.,2009 as cited in Shapiro SD,2010). Twin and familial aggregation studies 
suggest that genetic factors likely influence variation in pulmonary function in nonsmokers, 
but may not necessarily increase the risk of developing a clinical diagnosis of 
COPD(ATS,2010). 
3.1.3 Occupational and environmental exposures 
Farming and occupations with dusty environments increase the risk of developing chronic 
bronchitis two to threefold and, in combination with smoking, the risk increases to almost 
sixfold above average population(Melbostad et al.,1997;Salvi & Barnes,2009 as cited in 
Shapiro SD,2010). Environmental particulate air pollution and indoor smoke from biomass 
fuels have also been linked to COPD (Tashkin et al.,1984). There is strong evidence of an 
association between outdoor pollution(particulate matter, O3,NO2) and decreased 
pulmonary function (Gauderman et al,2004,2007; Rojas-martinez et al.,2007 as cited in 
Shapiro SD,2010). Exposure to air pollutants, occupational exposure, second-hand smoke 
exposure, fumes from burning biomass fuel, etc can produce deleterious effects on the 
airway. Oxidative stress, pulmonary and systemic inflammation, reduction in airway ciliary 
activity, amplification of viral infections, and increases in bronchial reactivity could lead to 
irreversible loss of pulmonary function over time and COPD(ATS,2010). 
3.1.4 Gender 
Epidemiological studies shows a male gender predominance related to the higher cigarette 
smoking habit or other inhaled toxins and occupational exposure among men within a 
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population(Buist et al,2007). Increase in smoking among women has diminished the 
difference among gender prevalence. Mortality may be peaking among men in the United 
States but, among women, mortality continues to rise and deaths from COPD among 
women now even exceeds those among men (Mannino et al.,2002,Silverman et al.,2000 as 
cited in Shapiro SD,2010).  
3.1.5 Asthma 
Accelerated loss of lung function has been noted among asthma patients(Lange et al.,1998; 
Peat et al.,1989 as cited in Shapiro SD,2010). Functional changes in both the small airways 
and the alveolar parenchyma have been reported. Many individuals have bronchial 
inflammation with features of both asthma and chronic bronchitis/emphysema( Gelb & 
Zamel,2000 as cited in Shapiro SD,2010). 
3.1.6 Socioeconomic status 
Morbidity and mortality rates have been shown to be inversely related to socioeconomic 
status(U.S. Department of Health and Human Resources,1984; Mannino & Buist,2007). 
Relative lack of awareness,diagnostic and therapeutic facilities and poorer health conditions 
may in part be connected to the socioeconomic status of the affected population. 
3.1.7 Developmental events 
Impairment in early lung growth and development appears to increase the risk of 
development of COPD(Weiss & Ware,1996 as cited in Shapiro SD,2010). Maternal smoking, 
low-birth weight and recurrent childhood respiratory infections have been associated with 
higher incidence of adulthood COPD.(Marossy et al.,2007; Shaheen,1998 as cited in Shapiro 
SD,2010) 
3.1.8 Dietary factors 
Observational studies strongly suggest that dietary factors, such as a higher intake of 
vitamin C and other antioxidants(carotenoids,Vitamin E,lutein, flavanoids) are significantly 
associated with better lung function(ATS,2010). Some dietary elements like fruits and 
vegetables(antioxidants), fish(omega-3 polyunsaturated fatty acids) and Vitamin D seem 
protective while processed foods like cured meats(nitrites) may be deleterious for lung 
function preservation(ATS,2010).  
3.1.9 Tuberculosis 
Pulmonary tuberculosis can lead to scarring and accelerated decline in lung 
function(Hnizdo et al.,2000 as cited in Shapiro SD,2010). Some population-based 
surveys(PLATINO and PREPOCOL) reported strong association between previous 
tuberculosis and a greater risk of COPD(Caballero et al.,2008; Menezes et al.,2007 as cited in 
Shapiro SD,2010). 
3.1.10 Intravenous drug abuse 
Emphysema is prevalent in approximately 2% of intravenous drugs abusers which can be 
attributed to pulmonary vascular damage possibly from the insoluble filler. Bullous cysts 
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are found in upper lobes of cocaine or heroin abusers whereas basilar and panacinar 
emphysema are associated with methadone and methylphenidate injections. 
3.1.11 Immune deficiency syndromes 
Human immunodeficiency virus (HIV) infection was found to be a risk factor for COPD, 
independent of confounding variables(Crothers et al.,2006 as cited in Shapiro SD,2010). 
Apical and cortical bullous lung damage occurs in autoimmune deficiency syndrome and 
Pneumocystis carinii infection. 
3.1.12 Vasculitis syndrome 
Hypocomplementemic vasculitis urticaria syndrome (HVUS)  and other associated 
conditions include angioedema, nondeforming arthritis, sinusitis, conjunctivitis, and 
pericarditis may be associated with obstructive lung disease. 
3.1.13 Connective-tissue disorders 
Several connective disorders have been implicated in causation of or co-existence with 
emphysema and poor lung function. Cutis laxa is a congenital disorder of elastin-
tropoelastin that is characterized by premature aging and occasionally emphysema. Marfan 
syndrome (autosomal dominant inherited disease of type I collagen), Ehlers-Danlos 
syndrome,Salla disease (autosomal recessive storage disorder with intralysosomal 
accumulation of sialic acid), Birt-Hogg-Dube’ syndrome and familial spontaneous 
pneumothorax syndrome(mutations in folliculin gene) have been associated with poor lung 
function, blebs, pneumothorax and emphysema(ATS,2010). 
4. Pathology 
4.1 Chronic bronchitis 
Chronic bronchitis is a clinical entity defined by a chronic productive cough for three 
months in each of two successive years in a patient in whom other causes of chronic cough 
have been excluded. It is characterised by an overlapping pathologic process of bronchial 
wall inflammation. The submucosal glands show dilated ducts and hypertrophy and 
hyperplasia. Reid index (the ratio of glandular to bronchial wall thickness) as well as goblet 
cell frequency and airway smooth muscle thickness is increased in chronic 
bronchitis(Reid,1960). The airway wall contains inflammatory cells predominated by 
macrophages and CD8+T lymphocytes. Bronchus-associated lymphoid tissue(BALT) is also 
present in late GOLD stages(Hogg & Timens,2009 as cited in Shapiro SD,2010). Increased 
numbers of neutrophils are found in the airway lumen and in the glands during episodes of 
exacerbations(Saetta et al.,1997;Thompson et al.,1989 as cited in Shapiro SD,2010). 
4.2 Emphysema 
Pulmonary emphysema, a pathological entity defined as destruction and enlargement of air 
spaces distal to the terminal bronchiole involving respiratory bronchioles, alveolar ducts, 
and alveoli. Cigarette smoking, inhaled irritants, recurrent infections and proteinase-
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antiproteinase imbalance lead to inflammatory cell recruitment, proteolytic injury to the 
extracellular matrix (ECM), and cell death. Alveolar walls become perforated and later due 
to incomplete and disorderly repair, become obliterated with coalescence of small distinct 
air spaces into abnormal and much larger air spaces, which is the pathological hallmark of 
emphysema (Shapiro & Ingenito,2005 as cited in Shapiro SD,2010). Emphysema has been 
classically described with absence of interstitial fibrosis to differentiate from restrictive lung 
diseases. However, scarring of the small airway subepithelial space and collagen 
accumulation around larger disrupted air spaces has been noted in emphysema.  
Various subtypes of emphysema have been described based on location and distribution of 
the lesions in the acinus (Pipavath et al.,2009 as cited in Shapiro SD,2010). In most patients, 
however, the process within the lung will be heterogeneous and in advanced stages, 
distinction becomes blurred. The following three patterns of emphysema are noted: 
4.2.1 Centriacinar (centrilobular, proximal acinar) emphysema 
Strongly associated with smoking, it begins in the respiratory bronchioles and spreads 
peripherally, primarily involving the upper and posterior parts of lungs(Leopold & 
Gough,1957;Thurlbeck,1991 as cited in Shapiro SD,2010). Focal emphysema, a form of 
centriacinar emphysema, occurs in persons with heavy exposure to inert dust such as coal 
dust (Morgan & Seaton,1984 as cited in Shapiro SD,2010).  
4.2.2 Panacinar emphysema 
Involves the entire alveolus uniformly and is predominant in the lower half of the 
lungs(Snider et al.,1962;Thurlbeck,1963,1976 as cited in Shapiro SD,2010). It is observed in 
patients with homozygous A1PI deficiency.  
4.2.3 Paraseptal (distal acinar) emphysema 
It usually involves the distal airway structures, alveolar ducts, and alveolar sacs  around the 
septae of the lungs or pleura(Hogg & Timens,2009;Kim et al.,1991 as cited in Shapiro 
SD,2010). Apical and giant bullae described in this subtype may lead to spontaneous 
pneumothorax or compression of adjacent lung tissue. 
4.3 Other pathologic variants mimicking emphysema 
4.3.1 Air space enlargement with pulmonary fibrosis 
It is commonly seen as an inconsequential lesion adjacent to scars but may be extensive 
arising as a complication of fibrosing diseases such as tuberculosis, silicosis, and sarcoidosis 
(Reid & Simon,1962;Thurlbeck,1991 as cited in Shapiro SD,2010). The spaces have dense 
fibrous walls and are mostly lined by bronchiolar epithelium(Akashi et al.,2009 as cited in 
Shapiro SD,2010). 
4.3.2 Bullae 
Bullae are marked focal dilation of respiratory air spaces that may result from coalescence of 
adjacent areas of severe panacinar emphysema, or from a ball-valve effect in the bronchi 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
124 
supplying an emphysematous area(Reid.1967;Thurlbeck,1976,1991 as cited in Shapiro 
SD,2010). 
4.3.3 Blebs 
These are intrapleural collections of air, a form of interstitial emphysema. They may arise 
from interstitial emphysema of the newborn period or pulmonary barotrauma complicating 
mechanical ventilation. Ruptured blebs can cause spontaneous pneumothorax. 
4.3.4 Cysts 
Cysts are air spaces lined by epithelium, which usually have the characteristics of bronchial 
epithelium., They are classically known as intrapulmonary bronchogenic cysts and usually 
occur near the tracheal bifurcation, but they may be seen more peripherally in the lung 
parenchyma(Reed & Sobonya,1974;Rogers & Osmer,1964 as cited in Shapiro SD,2010). 
4.3.5 Overinflation 
Air space distention with or without alveolar rupture and is often reversible. “Simple air 
space enlargement” in which there is no destruction or loss of orderly appearance of the 
lung acinus, occurs in the contralateral lung following pneumonectomy(Compensatory 
overinflation or emphysema). Air spaces, particularly alveolar ducts, enlarge with 
advancing age, resulting in what has been termed “senile emphysema”. Obstructive 
overinflation results from partial obstruction of a bronchus or bronchiole, when it becomes 
more difficult for air to leave the alveoli than to enter; there is a gradual accumulation of air 
distal to the obstruction, the so-called bypass, ball valve, or check valve type of obstruction. 
These conditions are listed in Table 1. 
 
Compensatory Hyperinflation: 
      Atelectasis 
   Post-lobectomy 
   Intrinsic Obstruction of Major Bronchus: 
      Tumor—benign or malignant 
      Postinflammatory stricture 
      Foreign body 
  Amyloid 
Extrinsic Obstruction: 
      Congenital 
      Aberrant vessel 
      Extrapulmonary sequestration 
      Tumor 
       Nodes 
Congenital Malformation of Bronchus:(Defective Cartilage or Mucosal Fold)  
  “Congenital Lobar Emphysema” 
Intrinsic Obstruction of Bronchioles: 
  Unilateral acquired Bronchitis  
  Bronchiolitis Obliterans 
Table 1. Conditions with overinflation mimicking Emphysema 
www.intechopen.com
 
Current Overview of COPD with Special Reference to Emphysema 
 
125 
4.4 Pediatric conditions with emphysema 
Some pediatric conditions display emphysematous pathologic findings resulting from a 
variety of developmental abnormalities in alveogenesis leading to impaired septation and 
alveolarization with consequent enlarged air spaces. Some are briefly described as below: 
4.4.1 Congenital lobar emphysema 
It is characterized by hyperinflation of one or more of the pulmonary lobes resulting from 
congenital deficiency of the bronchial cartilage, external compression by aberrant vessels, 
bronchial stenosis, redundant bronchial mucosal flaps or kinking of the bronchus caused by 
herniation into the mediastinum. The disease usually becomes apparent in the neonatal 
period but are delayed for as long as 5-6 mo in 5% of patients. The disease primarily 
involves lower lobes and occurs in familial preponderance. Treatment by immediate surgery 
and excision of the lobe may lifesaving, but some patients respond to medical treatment or 
selective intubation of the unaffected lung. 
4.4.2 Overinflation of all three lobes of the right lung 
Rarely produced by anomalous location of the left pulmonary artery impinging on the right 
main stem bronchus or occassionally with absent pulmonary valve type of tetralogy of 
Fallot and secondary aneurysmal dilatation of the pulmonary artery. Some neonates have 
lobar overinflation while on assisted ventilation, suggesting an acquired cause. 
4.4.3 Broncho-pulmonary dysplasia 
A form of chronic lung disease that develops in preterm neonates treated with oxygen and 
positive-pressure ventilation. Injury to small airways and pulmonary vasculature can 
interfere with alveolarization (alveolar septation), leading to alveolar simplification and 
reduction in the overall surface area for gas exchange. Premature birth and subsequent 
events (eg, exposure to oxygen, mechanical ventilation, inflammatory agents, infection) 
shifts the lung development towards premature maturation with an arrest in development 
and a loss of future gas exchange area. 
4.4.4 Pulmonary interstitial emphysema 
Collection of gases outside of the normal air passages and inside the connective tissue of the 
peribronchovascular sheaths, interlobular septa, and visceral pleura may result from 
alveolar or bronchiolar rupture commonly in premature infants on mechanical ventilation. It 
is a radiographic and pathologic diagnosis frequently in conjunction with respiratory 
distress syndrome, meconium aspiration syndrome, amniotic fluid aspiration and infection.  
4.4.5 Acute generalized overinflation of the lung 
Usually reported in infants and children secondary to a number of clinical conditions 
affecting bronchioles, including asthma, cystic fibrosis, acute bronchiolitis, interstitial 
pneumonitis, atypical forms of acute laryngotracheobronchitis, aspiration of zinc stearate 
powder, chronic passive congestion secondary to a congenital cardiac lesion, and miliary 
tuberculosis. 
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4.4.6 Bullous emphysematous blebs or cysts (pneumatoceles) 
They result from overdistention and rupture of alveoli during birth, or as sequelae of 
pneumonia and other infections. They have been observed in tuberculosis lesions during 
specific antibacterial therapy. 
4.4.7 Subcutaneous emphysema 
It results from any process that allows free air to enter into the subcutaneous tissue. It can 
also result from  pneumomediastinum or pneumothorax,fracture of the orbit, following 
tracheotomy, perforation in the esophagus or laryngopharyngeal area. Rarely, air is formed 
in the subcutaneous tissues by gas-producing bacteria. 
5. Etiopathogenesis 
The etiopathogenesis of COPD involves interplay of several over-lapping and co-existing 
injuries, defects, inflammation  and disorganized repair in a vicious cycle, ultimately leading 
to a chronic progressive impairment of lung function. These processes are shared by other 
airway and parenchymal diseases of lungs and aggravated by other pulmonary and 
systemic co-morbidities. The key steps involved are epithelial injury, inflammatory cell 
activation, protease-antiprotease imbalance, airway inflammation, goblet cell hypertrophy 
and hypersecretion, recurrent infection, acute exacerbations, attempts to disorganized repair 
and fibrosis, ultimately leading to chronic progressive permanent airway 
obstruction(Barnes,2008;Kasahara & Tuder,2000;MacNee & Tuder,2009;Rennard,2003 as 
cited in Shapiro SD,2010). 
5.1 Cigarette smoke induced inflammation 
Cigarette smoke initiates inflammation both by direct oxidative-irritative cellular injury and 
indirectly by recruiting several inflammatory cells in the air space(ATS,1962,Barnes et 
al.,2008;Shapiro & Ingenito,2005 as cited in Shapiro SD,2010). Neutrophils rapidly 
accumulate in the lung in response to exposure to cigarette smoke(Rennard,2003 as cited in 
Shapiro SD,2010). Recruitment occurs via stimulated epithelial cells and macrophages 
releasing TNF-ǂ and neutrophil chemokines CXCL1 and CXCL8 (IL-8) operating through 
the neutrophil receptor CXCR2(Barnes,2008 as cited in Shapiro SD,2010). Neutrophils 
contain proteinases like neutrophil esterase(NE) and Matix metalloproteinases(MMPs), 
particularly MMP-9, which are preformed and stored in granules and readily released upon 
activation. In addition to causing matrix destruction, proteinases generate fragments of 
ECM proteins such as collagen and laminin, which are also chemotactic for neutrophils, 
leading to a vicious feedback cycle of inflammation and tissue destruction(Adair-Kirk et 
al.,2003;Gaggar et al.,2008;Mydel et al.,2008 as cited in Shapiro SD,2010). 
COPD is characterized by a gradual, progressive accumulation of macrophages in the lung 
most apparent in respiratory bronchioles which is the primary site of centriacinar 
emphysema(Niewoehner et al.,1974 as cited in Shapiro SD,2010). Stimulated macrophages 
produce both neutrophil and macrophage chemokine and cytokines like macrophage 
chemotactic protein-1 (MCP-1; CCL2), which recruits more monocytes from the peripheral 
blood(Barnes,2008 as cited in Shapiro SD,2010).Macrophages produce a variety of MMPs, 
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particularly elastases such as MMP-9 and MMP-12, resulting in lung tissue injury. Degraded 
elastin fragments are chemotactic for macrophages, thus ensuing a self-propagating 
cycle(Houghton et al.,2006;Senior et al.,1980 as cited in Shapiro SD,2010). 
T cells lympocytes, especially CD8+ cells are increased in airway walls and alveoli of 
patients with COPD(Saetta et al.,1998 as cited in Shapiro SD,2010). Airway epithelial cells in 
smokers with COPD have increased expression of CXCL10 (IP-10), the ligand for CXCR3 
found on CD8+Tcells and thus may be the  activation pathway for macrophages to produce 
MMP-12(Grumelli et al.,2004;Saetta et al.,2002 as cited in Shapiro SD,2010). Cytotoxic T cells 
may target epithelial cells and induce cell death, particularly those with (latent) viral 
infection. 
Elastin fragments can serve as autoantigens and immunoglobulin G (IgG) autoantibodies 
with avidity for pulmonary epithelium have been found in patients with COPD(Feghali-
Bostwick et al.,2008;Lee et al.,2007 as cited in Shapiro SD,2010). Increased numbers of B cells 
and lymphoid follicles in the lung have raised interest in a possible autoimmune 
pathogenesis of COPD(Curtis et al.,2007;Taraseviciene-Stewart & Voelkel,2008 as cited in 
Shapiro SD,2010). Interplay of all these inflammatory pathways results in the tissue damage 
that keeps adding up over the years. 
5.2 Proteinase-antiproteinase imbalance 
Elastin and collagen is critical to the structural integrity of the lung. Experimental studies in 
animal lung models with instilled proteinases have replicated emphysematous 
changes(Gross et al.,1964 as cited in Shapiro SD,2010) resulting in an initial rapid increase in 
air space size due to direct elastolysis with diminution of lung elastin content at 24 hours 
followed by rapid restoration of total lung elastin to normal levels(Janoff et al.,1977;Snider et 
al.,1984 as cited in Shapiro SD,2010). The anatomic arrangement of the restored elastic fibers 
is grossly disordered (Kuhn & Senior,1978 as cited in Shapiro SD,2010). The tissue displays 
inflammation with neutrophils and macrophages with subsequent release of endogenous 
inflammatory mediators including IL-1ǃ and TNF-ǂ with endogenous proteolytic 
progression of the disease. Based on these studies and the association between A1PI 
deficiency with emphysema(Laurell & Eriksson,1963 as cited in Shapiro SD,2010), the 
proteinase-antiproteinase hypothesis proposed that the balance between matrix-degrading 
proteinases and their endogenous inhibitors determines whether the lung is protected or 
susceptible to proteolytic injury. 
Some proteinases such as NE and MMP-9 are bound to the surface of the neutrophil, they 
are resistant to complete inhibition by A1PI and tissue inhibitors of metalloproteinases 
(TIMPs). “Microenvironmental” concentration of proteinases and their proximity to the 
target site of matrix proteins when released from the neutrophil and macrophages, may 
explain how the balance tilts towards the proteinase function even in presence of adequate 
overall anti-proteinase in circulation(Owen & Campbell,1999 as cited in Shapiro SD,2010). 
There are four classes of proteinases, serine, cysteine, aspartic, and MMPs: 
5.2.1 Serine proteinases 
The serine proteinase Neutrophil elastase(NE) is suspected to be the major causative agent 
of tissue injury in COPD after the findings that patients deficient in its endogenous 
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inhibitor, A1PI, are at increased risk for emphysema and that instillation of NE caused 
emphysema in experimental models. NE also plays a role in airway disease as a potent 
secretagogue, facilitator of monocyte transvascular migration. NE is produced mainly by 
neutrophils, but also to a small degree by monocytes(Shapiro et al.,2003 as cited in Shapiro 
SD,2010). Cathepsin G (CG) and proteinase 3 (PR3) are other neutrophil-monocyte derived 
serine proteinases. Other than NE, minor inhibitors are Alpha2 microglobulin, secretory 
leukoprotease inhibitor (SLPI) and elafin.  
5.2.2 Matrix metalloproteinases (MMPs) 
MMPs are a family of 24 enzymes that require coordination of zinc at the active site, have 
overlapping substrate specificity, and are inhibited by TIMPs(Parks & Shapiro,2001 as cited 
in Shapiro SD,2010). Several MMPs degrade elastin and contribute to emphysema including 
MMP-2, MMP-9 (gelatinase A and B), MMP-7 (matrilysin), and MMP-12 (macrophage 
elastase). MMP-1, -8, -13 are also collagenases, and thus degrade another critical matrix 
component. 
Several MMPs have been associated with human COPD including MMP-1, MMP-9, MT1-
MMP, and MMP-12(Imai et al.,2001;Molet et al.,2005;Russell et al.,2002 as cited in Shapiro 
SD,2010). Macrophages have the capacity to produce MMP-1, MMP-3, MMP-7, MMP-9, MMP-
12, and MMP-19. MMP-12 is one of the most highly up-regulated genes in macrophages of 
human smokers(Atkinson & Senior,2003 as cited in Shapiro SD,2010). Role of MMPs in COPD 
pathogenesis is further supported by the epidemiologic prevalence of  polymorphisms of 
MMP in caucasian COPD patients(Hunninghake et al.,2009 as cited in Shapiro SD,2010). 
5.2.3 Cysteine proteinases 
Cathepsin L, S, and K are macrophage generated elastolytic enzymes. Cathepsin S also 
processes antigens in T cells(Riese et al.,1998 as cited in Shapiro SD,2010). Cathepsin K is the 
most potent elastase and collagenase. Cathepsin B is an epithelial cell product that has 
proapoptotic properties (Foghsgaard et al.,2001 as cited in Shapiro SD,2010). Cathepsins are 
inhibited by cystatins like Cystatin C which is the most ubiquitous cystatin found in all 
human tissues and body fluids. Cathepsins are being studied for their potential to contribute 
to COPD. 
5.3 Cell death 
Cell viability requires cell-matrix attachment via integrins, loss of matrix disrupts the 
contact and predisposes to cell death (termed “anoikis”). Experimental models show that 
noninflammatory cell death can initiate air space enlargement as demonstrated in studies 
involving rodent models with inhibition of vascular endothelial growth factor receptor or 
instillation of active caspase 3 in lung epithelial cell tissues(Aoshiba et al.,2003;Kasahara & 
Tuder;2000,Tang et al.,2004 as cited in Shapiro SD,2010). Thus cell death by injury or 
apoptosis can be an initiating trigger for emphysema. 
5.4 Disorganised and incomplete repair 
Injury is followed by aberrant repair of alveolar cells and matrix resulting in coalesced and 
enlarged air spaces with depleted and disordered parenchymal elastic fibers and excessive, 
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abnormally arranged collagen. Although following pneumonectomy, there is compensatory 
lung growth of the remaining lung in humans, whether the injured lung can ever reinitiate 
the process of septation and the intricate juxtaposition of matrix, epithelial, and endothelial 
cells to form functional alveoli during lung development is highly doubtful(Buhain & 
Brody,1973;Nolen-Walston et al.,2008;Shifren & Mecham,2006 as cited in Shapiro SD,2010). 
Elastin is the principal component of elastic fibers, which allows reversible extensibility and 
elastic recoil to the intercellular matrix of alveoli throughout the respiratory cycle.Elastin 
synthesis in the lung begins in the late neonatal period, peaks during early postnatal 
development, continues to slow through adolescence, and stops by adult life probably 
because of rapid mRNA degradation preventing expression of the protein.(Shapiro et 
al,1991;Swee et al,1995 as cited in Shapiro SD,2010). 
Animal model studies involving intratracheal injection of elastase show an acute depletion 
of elastin followed by rapid ECM synthesis, although the lungs develop 
emphysema(Karlinsky et al.,1983;Kuhn & Senior,1978). The newly synthesized elastic fibers 
appear disorganized, similar to the elastic fibers in human emphysema and thus 
emphasizing the role of impaired repair in its pathogenesis. Collagen is the other important 
ECM fiber to play a role in COPD. Total collagen content in the lung is actually increased in 
humans with COPD(Wright & Churg,1995 as cited in Shapiro SD,2010). Following tissue 
injury, excessive collagen deposition around the larger coalesced airspaces is noted. Small 
airway fibrosis is also prominent in COPD.These findings suggest that emphysema is not 
purely a destructive process but one of aberrant matrix turnover.  
5.5 Alpha-1 protease inhibitor (A1PI) deficiency 
A1PI , also known as alpha1-antitrypsin, is a serine proteinase inhibitor(serpin) that is 
produced mainly in the liver and found in the bloodstream and permeates tissues including 
the lung. A1PI inhibits various serpins including pancreatic trypsin, chymotrypsin but the 
main target is the neutrophil elastase(Brantly et al,1988;Travis,1989 as cited in Shapiro 
SD,2010). A1PI is also an acute phase reactant, with its serum concentration rising during 
pregnancy, during infections, after severe burns, and in the presence of malignant tumors. 
Smoking elevates the serum A1PI concentration by about 20%. 
A1PI is coded by a single gene with two alleles on chromosome 14q32.1 producing a 
glycoprotein composed of 394 amino acids. The A1PI gene is highly pleomorphic and more 
than 75 alleles are known, and they have been classified into normal (normal serum levels 
and normally functioning A1PI), null (undetectable A1PI in the serum), deficient (serum 
A1PI levels lower than normal), and dysfunctional (A1PI levels are normal but does not 
function normally)(Brantly et al,1988 as cited in Shapiro SD,2010). 
Most variants of A1PI arise point mutations with a single amino acid substitution. The Z 
variant(most common and severe disease) results from the substitution of a lysine for a 
glutamic acid at position 342, which changes the charge  and the electrophoretic mobility of 
the molecule(Yoshida et al,1976 as cited in Shapiro SD,2010). The mutant protein 
polymerizes and the aggregated form causes hepatic cell injury., The Z protein is also 
incompletely glycosylated, which may interfere with the protein's excretion from the liver 
into body fluids. (Ekeowa et al,2009;Gooptu & Lomas,2008 as cited in Shapiro SD,2010). The 
protein looses its physiologic function of inhibiting the NE. 
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The normal (M) alleles are found in about 90% of persons of European descent with normal 
serum A1PI levels(150 to 350 mg/dL or 20 to 48 µmol/dL); their phenotype is designated Pi 
MM. More than 95% of persons in the severely deficient category are homozygous for the Z 
allele(Pi ZZ) and have serum A1PI levels of 2.5 to 7 µmol/dL (mean, 16% normal)with an 
estimated prevalence between 1 in 1600 to 1 in 4000.This allele is mostly found in whites of 
northern European descent.  
Rarely observed phenotypes associated with low levels of serum A1PI include the 
following: Pi SZ and persons with nonexpressing alleles; Pi null, found in homozygous form 
as Pi null-null and found in heterozygous form with a deficient allele as Pi Z null. Persons 
with phenotype Pi SS have A1PI values ranging from 15 to 33 µmol/dL (mean, 52% of 
normal). The threshold protective level of 11 µmol/dL (35% of normal) is based on the 
knowledge that Pi SZ heterozygotes, with serum A1PI values of 8 to 19 µmol/dL (mean, 
37% of normal), rarely develop emphysema. Pi MZ heterozygotes have serum A1PI levels 
that are intermediate between Pi MM normals and Pi ZZ homozygotes (12–35 µmol/dL; 
mean, 57% of normal). There appears to be a small increase in risk of COPD in all Pi MZ 
individuals. 
COPD in homozygous A1PI deficiency patients is characterized by premature development 
of severe panacinar emphysema usually in the basilar regions of lung (Silverman & 
Sandhaus,2009). The onset of dyspnea occurs at a median age of 40 years about 1-2 decades 
earlier than rest of the population(Silverman & Sandhaus,2009 as cited in Shapiro SD,2010). 
However smoking has supradditive effect on poorer prognosis both with earlier onset 
severity and poorer prognosis of the disease(Janus et al,1985 as cited in Shapiro SD,2010). 
Radiographically, disease is more prominent in PiZZ patients and worse in basilar regions, 
sometimes hairline arcuate shadows separating markedly radiolucent areas in the lung 
bases from the less severely involved upper portions of the lungs (Gishen et al,1982;Hepper 
et al,1978 as cited in Shapiro SD,2010). 
A1PI deficiency is diagnosed by measuring the serum A1PI level, followed by Pi typing for 
confirmation. However, by the time they develop COPD symptoms, they already have 
significant liver disease often diagnosed in infancy/childhood with hepatomegaly or 
hepatosplenomegaly and evidence of cholestasis and elevation of hepatocellular enzymes. 
Screening for PiZZ in COPD patients is not recommended at present. Augmentation therapy 
with A1PI supplementation has been proposed for COPD patients with PiZZ genotype as 
per guidelines issued by ATS(ATS,1995) 
6. Natural history of disease 
The natural history of COPD as we know, is based on multiple longitudinal studies, 
although most spanned much shorter duration than the actual length of disease 
progression(Rennard & Vestbo,2008 as cited in Shapiro SD,2010). The classic study of 
Fletcher and colleagues and extrapolation of the data of other studies have yielded the 
“Fletcher-Peto curve,” which is basically a plot of FEV1 versus age (Fletcher,1976). The 
curve describes the gradually progressive permanent loss of lung function as age 
advances. Although it doesn’t include the concept of COPD in non-smokers and 
extrapulmonary effects of COPD, it serves a basic guide to understand the clinical course 
of the disease. 
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The natural history of COPD probably starts at pre-conception age related to genetics and 
intra-uterine lung development and growth, extending into early life events such as 
childhood and adolescent lung growth and injury from infections as well as later events 
such as adult lung exposures to cigarette smoke and occupational inhalants. 
Since the disease progresses slowly over the years, the earlier stages of the disease are often 
“silent” and mostly unnoticed by the patient. Exertional dyspnea, the earliest symptom, 
primarily from dynamic hyperinflation from exercise induced tachypnea, results in 
subconscious preferential sedentary lifestyle and thus avoiding the symptoms till later 
stage.(O’Donnell et al.,2001 as cited in Shapiro SD,2010) 
The intrauterine growth of lung includes development of conducting airways, gas exchange 
structures, including respiratory bronchioles and alveoli, but branching of alveolar wall 
continues postnatally for several years and usually complete by the first decade of life(Ten 
Have-Opbroek,1981 as cited in Shapiro SD,2010). Subsequent growth of the lung is due to 
increase in alveolar size and increase in airway diameter, but not in number. Maximal lung 
function is attained in young adulthood and remains relatively constant as a plateu for some 
years before declining in a slowly accelerating manner in older age(Weiss & Ware,1996 as 
cited in Shapiro SD,2010). The decline averages 20 mL/yr increasing in an accelerating 
manner and by age 50, there is an average drop of FEV1 by 1L. 
Smoking adversely affects the entire course, with interference in maximal lung capacity 
attainment if smoking starts in the early growth phase, to shortening of duration of the 
plateu phase, to rapid decline in lung function in later age(Burrows,1990 as cited in Shapiro 
SD,2010). This effect is very well depicted in the “Fletcher-Peto curve” shifting the plot 
downwards and earlier in age (Fletcher, 1976). The average COPD patient who smokes loses 
almost twice the lung function than usual(about 2 L of FEV1 over 50 years, an average 
decline of about 40 mL/yr). Acute exacerbations have descending step-ladder like effect 
with acute drops over short period with incomplete recovery resulting in faster drop of lung 
function(Burrows,1990 as cited in Shapiro SD,2010). Smoking has a predictable dose-
dependent deleterious effect on the lung function and cessation of smoking has beneficial 
slowing of disease progression if initiated early enough in course of disease (Anthonisen et 
al,1994;Buist et al.,1976 as cited in Shapiro SD,2010). 
Some individuals experience a rapid decline in lung function (Gottlieb et al.,1996 as cited in 
Shapiro SD,2010). Faster decline in lung function is noted in patients with low baseline lung 
function, less reversibility to ǃ2-agonists, more severe bronchial hyperresponsiveness, 
mucus production, male sex, and frequent exacerbations(ATS,2010). Identification of slow 
and rapid decliners in longitudinal studies such as the Lung Health Study has allowed 
exploration of biomarkers to characterize these groups. Importantly, systemic markers of 
inflammation have been associated with poorer lung function, and, in some, studies, with an 
increased rate of decline in lung function (Fogarty et al.,2007;Shaaban et al.,2006; Sin & 
Man,2003 as cited in Shapiro SD,2010).  
Although early stage COPD is difficult to diagnose, newer studies have shown a poorer 
prognosis among these population primarily from adverse cardiac events (Ashley et al., 
1975; Mannino et al., 2003 as cited in Shapiro SD,2010). The cardiac events may be linked to 
the extrapulmonary effects of COPD, especially elevated systemic inflammatory mediators. 
Identifying and treating this group thus can have valuable prognostic benefit. 
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With advanced disease, obvious exertional dyspnea, cough and frequent acute 
exacerbations dominate the picture. Morbidity and mortality increases with declining FEV1. 
Primary cause of mortality is cardiac events, however with advanced age and disease, 
pulmonary complications causing death, increase in proportion. Each exacerbation and the 
following recovery stage makes the patient most vulnerable to adverse outcomes as shown 
by the SUPPORT (Study to Understand Prognoses and Preferences for Outcomes and Risks 
of Treatments), which demonstrated a 49% 2-year mortality rate after hospital admissions 
with COPD exacerbation with CO2 retention(Connors et al.,1996). 
Various therapeutic and supportive medical and surgical intervention combined with 
rehabilitative measures help in alleviation of symptoms, slowing of pace of progression of 
disease and reduction of disability. Individualized plans for each patient based on the 
characteristic and stage of disease is important to achieve optimal results. 
7. Clinical presentation 
7.1 History 
COPD is a gradually progressive chronic disease presenting with clinically obvious 
symptoms late in the course, usually in their fifth decade of life with productive cough or 
breathlessness or acute chest illness. A1PI-deficient patients present earlier than other COPD 
patients usually in 3rd-4th decades and by then they have significant liver disease, which 
usually starts in childhood. 
Early COPD results in gradual progressive worsening of pulmonary function, which results 
in patients unknowingly avoiding exertional dyspnea (the most common early symptom of 
COPD) and fatigue by shifting their expectations and limiting their activity. Patients who 
have an extremely sedentary lifestyle but few complaints require further evaluation for 
possibility of underlying COPD as many patients reset their expectations with regard to 
health, termed “response shift”(Rennard et al,2002 as cited in Shapiro SD,2010). Generalised 
muscle weakness found in COPD patients can also contribute to this finding.  
Most patients usually present in the fifth or sixth decade of life by when they have dyspnea 
with mild exertion and usually the forced expiratory volume in 1 second (FEV1) has fallen 
to 50% of predicted. Moderate to severe COPD patients report variability in symptoms over 
the course of the day or week-to-week; morning is typically the worst time of day. Dyspnea 
is related to both respiratory (hyperinflation and impaired gas exchange) and extra-
respiratory (like muscle dysfunction, heart disease, anaemia and depression) features of 
COPD. 
The chronic cough is characterized by the insidious onset of sputum production, which 
occurs in the morning initially, but may progress to occur throughout the day. The sputum 
is usually mucoid, but becomes purulent during exacerbations. Hemoptysis complicating 
chronic bronchitis usually occurs in association with acute exacerbation. Lung cancer and 
tuberculosis needs to be ruled out in this scenario(Thompson et al,1992 as cited in Shapiro 
SD,2010). Wheezing may also be found in some patients due to co-existence of asthma or 
COPD alone. 
Acute exacerbations are characterized by increased cough, sputum, dyspnea, and fatigue, 
are increasingly frequent as the disease worsens. Each exacerbation may last for a few weeks 
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and followed by prolonged recovery over months and may be difficult to distinguish from 
other causes of dypsnea, cough, and/or sputum including pneumonia, congestive heart 
failure, pulmonary embolism, or pneumothorax(Spencer & Jones,2003 as cited in Shapiro 
SD,2010). 
A history of cigarette smoking or alternative inhalational exposure is usually found in 
majority of COPD patients. A1PI deficient patients may develop disease without smoking, 
however presence of smoking significantly worsens the course of disease. Some patients 
develop COPD without an obvious risk factor. Other historical features that may accompany 
COPD include certain comorbidities (eg, lung cancer, coronary artery disease, osteoporosis, 
depression, skeletal muscle weakness). Although most patients are usually obese, weight 
loss can also occur in COPD and is associated with a worse prognosis.  
7.2 Physical findings 
Physical findings in early COPD is highly non-specific and unreliable. Early stage patients 
may have coarse crackles and rhonchi. Wheezing may be found occasionally especially 
associated with asthma or acute exacerbations.  
The hallmark finding is obstruction of expiratory airflow. Measurement of the forced 
expiratory time maneuver is a simple bedside test and most consistent finding in 
symptomatic COPD. A forced expiratory time greater than 4 seconds indicates severe 
expiratory airflow obstruction. Objective measurement of airflow by spirometry, which is 
simple and accurate forms the basis of staging and follow-up of disease 
progression(Petty,2001). 
As the airway obstruction worsens, physical examination may reveal hyperinflation, 
decreased breath sounds, wheezes, crackles at the lung bases, and/or distant heart sounds. 
In addition, the diaphragm may be depressed and limited in its motion, and the 
anteroposterior diameter of the chest may be increased.  
Patients with end-stage COPD may present with barrel-shaped chest, increased span of 
hyperresonant  lung percussion, distended neck veins, full use of the accessory respiratory 
muscles of the neck and shoulder girdle, purse-lipped breathing, paradoxical retraction of 
the lower interspaces during inspiration (ie, Hoover's sign), emaciation, and frequently, 
inguinal hernias. They may adopt positions that relieve dyspnea, such as leaning forward 
with arms outstretched and weight supported on the palms(Tripod sign). This position 
stabilizes the shoulder girdle and helps to maximize intrathoracic volume. Late signs may 
include cyanosis, clubbing, asterixis due to severe hypercapnia, and an enlarged, tender 
liver due to right heart failure. 
8. Complications of COPD 
8.1 Pneumothorax 
Pneumothorax can precipitate severe dyspnea and acute respiratory failure and may be life 
threatening since they have only a marginal pulmonary reserve. Presence of giant bullae as 
part of disease predisposes to this complication. It can be difficult to treat if accompanied by 
a persistent air leak between the involved lung and the pleural space (bronchopleural 
fistula). 
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8.2 Pulmonary hypertension and Cor pulmonale 
Both resting and exercise mean pulmonary arterial pressures may be elevated. Prolonged 
pulmonary hypertension can give rise to chronic cor pulmonale in late stages. Alveolar 
hypoxia, respiratory acidosis, remodeling of the pulmonary vasculature with medial 
hypertrophy of muscular pulmonary arteries, increased viscosity of blood due to 
erythrocytosis, increased blood volume, left ventricular dysfunction and chronic pulmonary 
thromboembolic disease can all contribute to the pulmonary hypertension(Farber et 
al.,1982;Fletcher et al,1989 as cited in Shapiro SD,2010). Correction of hypoxia and acidosis 
by long-term oxygen therapy and pulmonary vasodilators may slow this process. 
8.3 Pneumonia 
COPD predisposes the lungs to pneumonia as part of acute exacerbation or as discrete 
event. (Ewing & Torres,1999;Griffith & Mazurek,1991 as cited in Shapiro SD,2010) 
8.4 Systemic complications and co-morbidities 
Ischemic cardiac disease is more common in COPD and cardiac events are the single largest 
cause of mortality in this population (Ashley et al.,1975;Mannino et al,2003 as cited in 
Shapiro SD,2010). Arrhythmia, congestive heart failure and aortic aneurysm are more 
common. COPD may lead to a hypercoagulable state due to erythrocytosis and systemic 
inflammation(mediated via TNF-ǂ, IL-6) posing greater risk of stroke, pulmonary embolism 
and deep vein thrombosis(Bhowmik et al,2000;Wouters et al.,2002 as cited in Shapiro 
SD,2010). Weight loss, osteoporosis, skin wrinkling, anemia, fluid retention and depression 
are some of the other systemic co-morbidities commonly associated with COPD. Major 
chronic diseases (e.g. congestive heart failure, dementia, ischaemic heart disease, stroke, 
diabetes, cancer, asthma, COPD, depression and hypertension) were associated with at least 
one of the other diseases in 60–90% of cases(Charlson et al.,2007 as cited in Shapiro SD,2010). 
A major question is whether coexisting chronic illnesses found in COPD subjects are merely 
related to common risk factors (e.g. aging, tobacco smoking and genetic predisposition) or 
are also consequences, at least in part, of the pulmonary and/or systemic inflammation that 
characterise COPD. 
9. Diagnosis and laboratory work-up 
9.1 Spirometry 
Objective measurement of airflow obstruction is the mainstay of workup for diagnosis, 
staging and follow-up of COPD(Petty,2001). The most important values measured are the 
forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) or the 
forced expiratory volume after 6 seconds, (FEV6 ), which is the recommended substitute for 
FVC(Enright et al.,2002 as cited in Shapiro SD,2010). COPD is confirmed when a patient, 
who has symptoms that are compatible with COPD, is found to have airflow obstruction 
(FEV1/FVC ratio less than 0.70 and an FEV1 less than 80 percent of predicted) and there is 
no alternative explanation for the symptoms and airflow obstruction (eg, bronchiectasis, 
vocal cord paralysis, tracheal stenosis). If airflow is abnormal, postbronchodilator testing 
should be performed. Correction of airflow to the normal range suggests a diagnosis of 
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asthma and could exclude COPD. Because of variability in the FVC (or FEV6) measure, the 
FEV1/FVC ratio can establish a diagnosis of obstruction but is not useful to monitor disease 
progression(GOLD,2006). FEV1/FVC ratio is the basis for GOLD staging of COPD(see Table 2). 
 
Stage 
 
FEV1*/FVC**(in %) FEV1*(in % of predicted) 
I: Mild COPD <70 %  ≥80 %  
II: Moderate COPD <70 % 50 % to <80% 
III: Severe COPD <70 % 30% to <50% 
IV: Very Severe COPD <70 % <30%  or  <50% with chronic 
respiratory failure*** 
*FEV1: forced expiratory volume in one second; **FVC: forced vital capacity; ***Chronic respiratory 
failure: arterial partial pressure of oxygen (PaO2) less than 60 mm Hg (8.0 kPa) with or without arterial 
partial pressure of CO2 (PaCO2) greater than 50 mm Hg (6.7 kPa) while breathing air at sea level.  
Table 2. Staging of severity of COPD (GOLD,2006) 
Other spirometric findings include decreased inspiratory capacity and vital capacity, 
accompanied by increased total lung capacity, functional residual capacity, and residual 
volume are indicative of hyperinflation. The single breath carbon monoxide diffusing 
capacity (DLCO) decreases in proportion to the severity of emphysema because of the 
destruction of the alveoli and the loss of alveolar capillary bed.(Bates,1989) 
9.2 Arterial blood gas 
Arterial blood gases reveal mild or moderate hypoxemia without hypercapnia in the early 
stages of COPD. In the later stages of the disease, hypoxemia tends to become more severe 
and may be accompanied by hypercapnia with increased serum bicarbonate 
levels(Bates,1989). The changes in ABG represent ventilation perfusion mismatch, which 
may be worsened during exercise, sleep and episodes of exacerbation. 
9.3 Alpha1-antitrypsin level 
Of the approximately 75 different alleles for alpha1-antitrypsin (AAT) deficiency variants, 
10-15 are associated with serum levels below the protective threshold of 11 µmol/dL. The 
most common severe variant is the Z allele, which accounts for 95% of the clinically 
recognized cases of severe AAT deficiency. The diagnosis of severe AAT deficiency is 
confirmed when the serum level falls below the protective threshold value (ie, 3-7 
µmol/dL). Specific phenotyping is reserved for patients in whom serum levels are 7-11 
µmol/dL or when genetic counseling or family analysis is needed.  
9.4 Sputum evaluation 
In patients with stable chronic bronchitis, the sputum is mucoid and the predominant cells 
are macrophages(Miravitlles,2002;Sethi et al.,2002 as cited in Shapiro SD,2010). With an 
exacerbation, the sputum becomes purulent, with excessive neutrophils and a mixture of 
organisms visualized through Gram staining. Streptococcus pneumoniae and Haemophilus 
influenzae are pathogens frequently cultured during exacerbations. 
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9.5 Imaging studies 
Chest radiographs and CT-scan of chest are the mainstay of COPD imaging. Although not 
contributing to diagnosis of COPD, they may add valuable information regarding severity, 
stage and special findings during the course of disease. 
9.5.1 Chest X-ray 
Radiographic features suggestive of COPD are prominent usually in advanced disease and 
include: 
i. Signs of hyperinflation: Prominent hilar vascular shadows and encroachment of the 
heart shadow on the retrosternal space, increased radiolucency of the lung, a flat 
diaphragm, and a long and narrow heart shadow on a frontal radiograph, accompanied 
by a flat diaphragmatic contour may be seen.  
ii. Bullae, defined as radiolucent areas larger than one centimeter in diameter and 
surrounded by arcuate hairline shadows. They are due to locally severe disease.  
iii. Rapidly tapering vascular shadows and cardiac enlargement may become evident only 
on comparison with previous chest radiographs. These findings are due to pulmonary 
hypertension and cor pulmonale, which can be secondary to COPD. 
9.5.2 Computed tomography 
High-resolution CT (HRCT) scanning is more sensitive than standard chest radiography and 
is highly specific for diagnosing emphysema and outlines bullae that are not always 
observed on radiographs. CT can visualise whether the emphysema is centriacinar or 
panacinar(Hasegawa et al.,2006;Nishino et al.,2010;Washko et al.,2008 as cited in Shapiro 
SD,2010). A CT scan is not indicated in the routine care of patients with COPD but is helpful 
when the patient is being considered for a surgical intervention such as bullectomy or lung-
volume reduction surgery(Fishman et al,2003 as cited in Shapiro SD,2010).  
10. Stage of disease severity and progression 
The GOLD staging system is based on the FEV1/FVC ratio(see Table 2). It has been criticized 
for underestimating the importance of the extrapulmonary manifestations of COPD in 
predicting outcome(GOLD,2006;Bourdin et al,2009). The BODE index addresses this 
criticism. The four factors included in the BODE index are weight (BMI), airway obstruction 
(FEV1), dyspnea (Medical Research Council dyspnea score), and exercise capacity (six-
minute walk distance)(see Table 3). This index provides better prognostic information than 
the FEV1 alone to assess an individual's risk of death or hospitalization due to COPD. 
However, it is not used to guide therapy.  
A component of disease assessment that is used in research studies is to evaluate the 
impact of airflow limitation on quality of life. The St. George's Respiratory Questionnaire 
(SGRQ) is a 76 item questionnaire that includes three component scores (ie, symptoms, 
activity, and impact on daily life) and a total score(Jones et al.,1991). It has been validated 
in patients with COPD, asthma, and bronchiectasis. Another questionnaire based 
instrument to assess quality of life is the Chronic Respiratory Disease Questionnaire 
(CRDQ) (Guyatt et al.,1987). 
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Parameter 0 Points 1 Point 2 Points 3 Points 
Body: BMI >21 ≤21 — — 
Obstruction: FEV1 (% 
predicted) 
≥65% 50–64% 36–49% ≤35% 
Dyspnea: MMRC score 0-1 2 3 4 
Exercise: 6-minute walk 
distance (meters) 
≥350 250–349 150–249 ≤149 
BMI, body mass index; FEV1, forced expiratory volume in 1 second. 
Table 3. BODE Index for Staging COPD (Celli et al.,2004) 
11. Treatment 
Treatment of COPD encompasses health promotion, prevention, control of symptoms and 
exacerbations, rehabilitation and palliation. Treatment plan needs to be individualized 
according to the stage and characteristics of the disease, age, co-morbidities in each patient. 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that 
pharmacologic and nonpharmacologic therapies should be added in a stepwise fashion to 
control symptoms, decrease exacerbations, and improve patient function and quality of life 
(GOLD,2006). Patient should be educated about the disease and should be encouraged to 
participate actively in therapy and understand the need of proper dosing and timing of 
medications as well as proper inhaler technique is essential. 
ATS Statement (1995) recommended symptomatic management after the patient presented 
to the healthcare system with specific complaints(ATS,1995). However, new evidence 
suggests that the “pre-symptomatic” phase individuals progressively loose lung function in 
these years and also have poorer prognosis in terms of cardiac outcomes and hence earlier 
and more aggressive diagnosis and appropriate treatment of these previously unidentified 
individuals can help, not only by slowing progression but also by improving symptomatic 
control(GOLD,2006). 
Mainstays of drug therapy of stable COPD are bronchodilators, primarily beta agonists and 
anticholinergics, and inhaled glucocorticoids, given alone or in combination depending 
upon the severity of disease and response to therapy. Attention to co-morbidities like heart 
disease, depression, osteoporosis and rehabilitation for acceptable quality of life is also 
important. Reduction of risk factors like cigarette smoking and occupational exposure 
should be a central feature of every comprehensive treatment plan. The only medical 
therapies that clearly reduce disease progression and mortality are smoking cessation and 
supplemental oxygen (NOTT,1980). 
11.1 Cessation of cigarette smoking 
Smoking cessation is the single most effective therapy for the majority of COPD 
patients(Anthonisen et al,1994;Department of Health and Human Services(US),2008). The 
transition from smoking to nonsmoking status involves following five stages: 
precontemplation, contemplation, preparation, action, and maintenance. Smoking 
intervention programs include self-help, group, physician-delivered, workplace, and 
community programs. Setting a target date to quit may be helpful. Physicians and other 
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health care providers should participate in setting the target date and should follow up with 
respect to maintenance. Successful cessation programs should include patient education, 
target date to quit, follow-up support, relapse prevention, advice for healthy lifestyle 
changes, social support systems, pharmacological agents. 
According to the US Preventive Services Task Force(USPSTF) guidelines, recommends “5-
A” approach to counseling that includes i)Ask about tobacco use, ii)Advise to quit through 
personalized messages, iii)Assess willingness to quit, iv)Assist with quitting, v)Arrange 
follow-up care and support. Behavioral counseling and pharmacotherapy are most effective 
when used together.(USPSTF,2009) 
Supervised use of pharmacologic agents is an important adjunct as withdrawal from 
nicotine may cause unpleasant adverse effects during the first weeks after quitting smoking. 
Nicotine replacement therapies are available in the form of chewing gum and transdermal 
patches to counter the withdrawal symptoms(U.S. Public Health Service Clinical Practice 
Guideline,2008). Long-term success rates have been 22-42%, compared with 2-25% with 
placebos. The use of an antidepressant medication, bupropion (Zyban,150 mg bid) has been 
shown to be effective for smoking cessation and may be used in combination with nicotine 
replacement therapy. Varenicline (Chantix), is a partial agonist selective for ǂ4, ǃ2 nicotinic 
acetylcholine receptors and action is thought to result from partial agonist activity at a 
nicotinic receptor subtype while simultaneously preventing nicotine binding. Nortriptyline 
and clonidine have also been proposed to help in cessation of smoking (U.S. Public Health 
Service Clinical Practice Guideline,2008). 
11.2 Pharmacologic treatment 
The U.S. Food and Drug Adminstration (FDA) recommends five treatment end points be 
considered for COPD: improvement in airflow obstruction, providing symptom relief, 
modifying or preventing exacerbations, altering disease progression (including mortality), 
and modifying lung structure. Effective treatment of the COPD patient requires effective 
integration of pharmacologic treatment and nonpharmacologic therapy, most importantly 
pulmonary rehabilitation. 
11.2.1 Bronchodilators 
Bronchodilators are the mainstay of any COPD treatment plan. The mechanism of action is 
primarily by dilating airways and thereby decreasing airflow resistance increasing airflow 
and decreasing dynamic hyperinflation which is the origin of early stage symptoms. Many 
patients with COPD will have reduced dyspnea and improved exercise tolerance with 
bronchodilator therapy, even if improvement in resting spirometry is very 
modest(O’Donnell,2000 as cited in Shapiro SD,2010). Unlike asthma, COPD patients mostly 
need bronchodilators both on a chronic basis as well as for “rescue”. All symptomatic 
patients with COPD should be prescribed a short-acting bronchodilator for as-needed basis 
and a regularly scheduled long-acting bronchodilator should be added if symptoms are 
inadequately controlled. Bronchodilators include beta agonists, anticholinergics, and 
theophylline, which is used less often. 
The initial choice of agent remains debated. Historically, ǃ2 agonists were considered first 
line and anticholinergics added as adjuncts. Studies have shown combination therapy 
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results in greater bronchodilator response and provides greater relief. The degree of 
bronchodilation achieved by short-acting beta agonists and anticholinergics is additive. The 
adverse effect profile may help guide therapy. 
i. Beta2(ǃ2)-agonists: 
This group of medications bind to the ǃ-adrenergic receptor present on airway smooth 
muscle, resulting in bronchodilation and improvement in airflow. They may also help by 
increasing ciliary beating frequency and improving mucus transport and may improve 
endurance of fatigued respiratory muscles(Nava et al,1992;Santa Cruz et al,1974 as cited in 
Shapiro SD,2010). 
Beta agonists are available in short-acting and long-acting inhaled formulations. The short-
acting-ǃ agonists(SABA) like albuterol, its racemer levalbuterol, pirbuterol and terbutaline, 
have a relatively rapid onset of action after inhalation, in about 5 to 15 minutes, and the 
bronchodilation lasts for 2 to 4 hours. Long-acting ǃ-agonists (LABAs) like salmeterol, 
formoterol, arformoterol and indacaterol have a longer onset  and bronchodilation lasting 
for up to 12 hours or more. Salmeterol has also shown  anti-inflammatory effects, to reduce 
edema, and to reduce airway epithelial cell injury in model systems. 
Inhaled route is preferable owing to more favorable ratio of therapeutic effect to undesirable 
side effects(Shim & Williams,1983 as cited in Shapiro SD,2010). A metered dose inhaler 
(MDI), dry powder inhaler (DPI) is the preferred mode to deliver a bronchodilator 
medication by inhalation as it simplifies therapy, improves compliance, and may reduce 
extra medication usage and patient cost. Nebulizers may be more effective in patients too 
weak to use an inhaler device, in those with altered mental status, or in those whose 
inspiratory capacity is too limited to permit effective inhalation (Tenholder et al,1992 as 
cited in Shapiro SD,2010). 
Benefits of treatment include improvement in airflow obstruction and symptom relief. 
Although the  magnitude of improvement is less and incomplete as compared to asthma 
patients, 25-30% patients achieve “positive bronchodilator response” as defined by the ATS. 
Improvement in FEV1( about 200- to 300-mL) and symptoms assessed by SGRQ have been 
elicited in multiple randomized placebo-controlled trials(Appleton et al,2006;Calverley et 
al,2003;Rodrigo et al,2008 as cited in Shapiro SD,2010). Modest benefit is noted in prevention 
of exacerbations with LABAs to the tune of 20-30% reduction in frequency of 
exacerbations(Appleton et al,2006;Sin et al,2003 as cited in Shapiro SD,2010). However, they 
have no effect on disease progression and alteration of lung structure(Calverley et al.,2007 as 
cited in Shapiro SD,2010). 
Side-effects commonly include tremor, palpitations, anxiety, and insomnia. Ventricular 
arrhythmias and hypokalemia may also occur. These effects are dependent on systemic 
absorption and hence, spacer devices, DPIs,MDIs are preferable. R-enantiomer of albuterol, 
levalbuterol was promoted widely based on the possibility to have lesser side effects such as 
tachycardia and tremors as well as lacking the inflammatory effect of the S-enantiomer. The 
small difference noted in studies has raised doubts of its clinical relevance(Donahue et 
al,2008 as cited in Shapiro SD,2010).  
A significant proportion of COPD patients have concurrent cardiac co-morbidities and 
although recent studies have failed to show any clinically significant adverse outcome of ǃ2 
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agonists, caution is warranted.(Cazzola et al,1998;Anthonisen et al,2002 as cited in Shapiro 
SD,2010) 
ii. Anti-cholinergics: 
Anticholinergic agents block M2 and M3 cholinergic receptors and result in bronchodilation 
(Rennard,2000 as cited in Shapiro SD,2010). In airway smooth muscle cells, acetylcholine 
stimulates the production of neutrophil chemotactic activity and anticholinergics could, 
theoretically, have anti-inflammatory action (Koyama et al,1992;Wessler & Kirkpatrick,2001 
as cited in Shapiro SD,2010). 
Short-acting anticholinergic agents like ipratropium and oxitropium improve lung function 
and symptoms. In double-blinded studies, ipratropium improved lung function, increased 
exercise capacity, decreased dyspnea, and decreased cough when compared to placebo. 
Ipratropium produces bronchodilation in 10 to 15 minutes and lasts for 4 to 6 hours. 
Tiotropium is a longer-acting anticholinergic because it dissociates from the receptor 
extremely slowly achieving peak bronchodilator activity after 1 to 2 hours, but duration of 
action lasts long enough for once daily dosing. When administered chronically, the 
bronchodilator effect of tiotropium increases with daily dosing and is maximal after 1 week 
(Hansel & Barnes,2002;Littner et al,2000 as cited in Shapiro SD,2010). It is relatively selective 
for M3 receptor, and this may have better clinical efficacy as it doesn't alter the M2 mediated 
feedback inhibition of acetylcholine (On et al,2001 as cited in Shapiro SD,2010). The 
Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial 
studied the effects of use over a 4-year period and showed improvements in lung function, 
quality of life, and exacerbations but did not show a decrease in the rate of decline of lung 
function (Tashkin et al.,2008). 
Benefits of treatment are similar to beta-agonist agents including improvement in airflow 
obstruction and symptom relief. Tiotropium improves airflow and lung volumes, reduces 
dyspnea, and improves health status and exercise performance(Tashkin et al,2008). In 
combination with albuterol tiotropium has been reported to reduce risk of COPD 
exacerbation to the magnitude of the risk reduction by 20% to 25%( Niewoehner et 
al,2005;Sin et al,2003 as cited in Shapiro SD,2010). However, as with other bronchodilators, 
anticholinergics have no effect on disease progression and alteration of lung structure. 
Reported adverse effects include dry mouth, metallic taste, and prostatic symptoms. 
Equivocal data exist regarding possible increased adverse cardiac events with chronic use of 
anti-cholinergic agents. 
iii. Theophylline: 
Theophylline is the only methylxanthine currently used to treat COPD patients. It has 
modest bronchodilator activity, but it also has additional potentially beneficial effects 
including anti-inflammatory, modest inotropic and diuretic effects, and may also augment 
skeletal muscle strength(Barnes,2003;Culpitt et al,2002 as cited in Shapiro SD,2010). Dose-
related adverse effects of theophylline include nausea and vomiting, seizures, and 
arrhythmias. Its use is also complicated by many drug interactions and concurrent 
morbidity that affecting liver and cardiac function can alter theophylline levels. The 
therapeutic index of theophylline is narrow and desired serum levels are 8 to 12 µg/mL. 
Dose-related adverse effects of theophylline include nausea and vomiting, seizures, and 
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arrhythmias.Hence, use of theophylline is usually limited to an add-on therapy when 
symptoms continue in patients with more severe disease despite the use of other treatments. 
11.2.2 Choice of bronchodilator and combination therapy 
Historically, ǃ2 agonists were considered first line and anticholinergics added as adjuncts. 
Most patients in GOLD stage I disease will have acceptable relief of symptoms with one 
short acting bronchodilator used on as needed basis. Combination therapy with short and 
long acting ǃ2-agonists and anticholinergics is supported by trials indicating greater 
bronchodilator response and achieving better symptom relief(Cazzola et al,2004;CIAS 
Group,1994;VanNoord et al.,2000 as cited in Shapiro SD,2010). In patients with GOLD stage 
II and above, whose symptoms are not well-controlled with a single long-acting 
bronchodilator, the combination of both an anticholinergic and a ǃ2-agonist long-acting 
bronchodilator may provide better symptom relief and improve quality of life 
index(ATS/ERS Task Force,2004;GOLD,2006).  
SABA, LABA, anticholinergics have been tried in various combinations and data suggests 
improved FEV1 and symptom control with combinations than either agent alone. The choice 
and order of agents can be guided by response, side-effects and co-morbidity profile 
(ATS/ERS Task Force, 2004; GOLD, 2006). Although clinical responses among individual 
patients may vary, poor compliance and ineffective use of the device must be considered 
before changing medications. 
11.2.3 Anti-inflammatory medications 
COPD is characterized by both airway and systemic inflammation as discussed in the 
pathogenesis and the primary reason of disease progression. Bronchodilators achieve 
temporary symptom control but have failed to show any effect on the underlying 
inflammation. Corticosteroids are by far the leaders of this class of medication, and some 
newer phosphodiesterases have shown promise. 
i. Corticosteroids: 
Inhaled glucocorticoids decrease frequency of exacerbations and modestly slow the 
progression of respiratory symptoms, but appear to have little impact on lung function and 
mortality. Because of their lack of effect on bronchodilation, inhaled glucocorticoids can be 
used only as part of a combined regimen, but are not as sole therapy. 
Benefits from therapy include reduction in the frequency and severity of exacerbations of 
COPD by 25-30%, comparable to LABAs(Calverley et al.,2003,2007;Szafranski et al,2003 as 
cited in Shapiro SD,2010). Effect on improvement of airflow obstruction and symptom relief 
is minimal, although some additive benefit is reported for combination therapy with 
LABAs(Burge et al,2000;Pauwels et al,1999 as cited in Shapiro SD,2010). Though the anti-
inflammatory effect promises possible alteration of disease progression and slowing of 
decline in FEV1, studies have failed to show any such benefit(Highland et al,2003;Soriano et 
al,2007;Sutherland et al.,2003 as cited in Shapiro SD,2010). Some studies have reported 
equivocal reduction in hospital admission and mortality rates(Sin & Tu,2001;Soriano et 
al,2002 as cited in Shapiro SD,2010). No study has proven any effect on lung structure 
remodelling. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
142 
Inhaled corticosteroids are only minimally absorbed and therefore systemic adverse effects 
are limited. Local effects include oral candidiasis and dysphonia(Pauwels et al,1999 as cited 
in Shapiro SD,2010). Systemic effects include increased bruising and reduced bone density, 
and possible susceptibility for pneumonia(Calverley et al.,2007 as cited in Shapiro SD,2010). 
Appropriate caution and monitoring is recommended although the clinical importance of 
these effects remains uncertain. 
Systemic steroids have been widely used in the treatment of acute exacerbation of COPD. A 
meta-analysis concluded that systemic corticosteroids significantly reduced treatment 
failure and need for additional medical treatment and increased the rate of improvement in 
lung function and dyspnea over the first 72 hours(Rice et al,2000 as cited in Shapiro 
SD,2010). The use of oral steroids in persons with chronic stable COPD is not recommended 
given the adverse effect profile, which includes hypertension, glucose intolerance, 
osteoporosis, fractures, and cataracts, among others(Burge et al,2003 as cited in Shapiro 
SD,2010). 
Inhaled glucocorticoids are typically used in combination with a long-acting bronchodilator 
for patients in GOLD stage III-IV, who have significant symptoms or repeated 
exacerbations, despite an optimal bronchodilator regimen. Steroids may be introduced 
earlier if there are signs of inflammation or an asthmatic component to the COPD(Ferguson 
et al.,2008 as cited in Shapiro SD,2010). In the TORCH (Toward a Revolution in COPD 
Health) trial involving patients with moderate to severe COPD, salmeterol plus fluticasone 
significantly improved the lung function, health status, and the rate of exacerbations 
compared to placebo, salmeterol alone, or fluticasone alone(Calverley et al.,2007). It also 
minimally decreased mortality compared to placebo (10.3 versus 12.6 percent, hazard ratio 
0.81, 95% CI, 0.67-0.98). The Investigating New Standards for Prophylaxis in Reduction of 
Exacerbations (INSPIRE) trial  included 1323 patients with stable, mostly severe COPD and 
results failed to show significant benefits of combining inhaled steroids with 
LABAs(Wedzicha et al.,2008).  
“Triple inhaler therapy” - with a long-acting beta agonist plus an inhaled glucocorticoid 
plus a long-acting anticholinergic is often used in refractory COPD patients. This approach 
is supported by some studies(Tashkin et al.,2008). These data are insufficient to warrant a 
change in the current guidelines in which the first step is initiation of a long-acting 
bronchodilator alone and then if response is inadequate or disease advances, to introduce a 
combination of long-acting beta agonist plus an inhaled glucocorticoid. 
ii. Phosphodiesterase inhibitors :  
Phosphodiesterase-4 (PDE-4) inhibition decreases inflammation and promotes airway 
smooth muscle relaxation. Cilomilast and roflumilast are highly specific, oral, second-
generation PDE-4 inhibitors being considered for use in patients with asthma and 
COPD(Gamble et al.,2003;Profita et al.,2003 as cited in Shapiro SD,2010). Recent trials have 
supported their inclusion in COPD combination treatment plans(Calverly et al.,2009;Chong 
et al.,2011as cited in Shapiro SD,2010). Several randomized, double-blind, placebo-
controlled multicenter trials revealed increased FEV1 (P < .0001) and the rate of COPD 
exacerbations was reduced by 17% (P <.0003) in patients who received roflumilast compared 
with placebo. Additional studies are necessary before PDE-4 inhibitors can be recommended 
for routine use in patients with stable COPD. 
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iii. Cromolyn Sodium Nedocromil and Leukotriene Antagonists : 
There are no supportive data advocating a beneficial role for cromolyn, nedocromil, or 
cysteinyl leukotriene antagonists in treating COPD(DeJong et al,1994 as cited in Shapiro 
SD,2010).  
11.2.4 Adjuvant pharmacologic agents 
i. Augmentation therapy for A1PI deficiency: 
The treatment strategies for A1PI deficiency involve reducing the neutrophil elastase 
burden, primarily by smoking cessation, and augmenting the levels of A1PI. Available 
augmentation strategies include pharmacologic attempts to increase endogenous production 
of A1PI by the liver (ie, danazol, tamoxifen) or administration of purified A1PI by periodic 
intravenous infusion or by inhalation. Tamoxifen can increase endogenous production of 
A1PI to a limited extent, so this may be beneficial in persons with the PISZ phenotype. 
Intravenous augmentation therapy is the only available approach that can increase serum 
levels to greater than 11 mmol/L, the protective threshold. Studies show that the infusions 
can maintain levels of more than 11 mmol/L, and replacement is administered weekly (60 
mg/kg), biweekly (120 mg/kg), or monthly (250 mg/kg) (Buist et al,1989;Sandhaus,2009 as 
cited in Shapiro SD,2010). Uncontrolled observations of patients suggest that the FEV1 may 
fall at a slower rate in patients who receive A1PI replacement. It seems reasonable to weigh 
carefully the advantages and disadvantages of augmentation therapy and to reach a 
decision jointly with elderly persons or with those with severe lung function impairment 
(FEV1 values < 0.8 L)(Buist et al,1989 as cited in Shapiro SD,2010).  
ii. Mucoactive and expectorant agents:  
Mucolytic agents like acetylcysteine, dornase(DNAse), guaifenesin reduce sputum viscosity 
and improve secretion clearance. however, studies have failed to justify a role for these 
medications in management of COPD(Decramer et al,2005 as cited in Shapiro SD,2010). The 
role of oral expectorants like guaifenesin in promoting mucous clearance in COPD patients 
remains controversial. 
iii. Antibiotic therapy: 
Chronic infection or colonization of the lower airways with S pneumoniae, H influenzae, 
and/or Moraxella catarrhalis is common and in later stage disease, with Gram-negative 
organisms such as Pseudomonas. Macrolides like erythromycin, may have additional 
antiinflammatory effects. Patients whose COPD is associated with, bronchiectasis may 
benefit from chronic antibiotic therapy. However, at present, chronic antibiotics are not 
recommended for stable COPD management.  
The use of antibiotics for the treatment of acute COPD exacerbations and pneumonias is 
well supported (Adams et al.,2008). The patients who benefited most from antibiotic therapy 
were those with exacerbations that were characterized by at least 2 of the following: 
increases in dyspnea, sputum production, and sputum purulence (The Winnipeg criteria). 
iv. Vaccine prophylaxis: 
Infection is a common cause of COPD exacerbation and vaccination is the most effective 
way of prophylaxis. Pneumococcal polysaccharide vaccine should be offered to patients 
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with COPD who are ≥65 years old, or who are younger than 65 years with a forced 
expiratory volume in one second (FEV1) less than 40 percent. An annual influenza vaccine 
should be given to all patients with COPD. 
11.2.5 Supportive management 
i. Oxygen therapy: 
Chronic hypoxemia may develop in patients with severe stable COPD (GOLD stage IV). 
Two landmark trials, the British Medical Research Council (MRC) study and the National 
Heart, Lung, Blood Institute's Nocturnal Oxygen Therapy Trial (NOTT) showed that long-
term oxygen therapy improves survival by 2-fold or more in hypoxemic patients with 
COPD(Kvalle,1980;Medical Research Council Working Party,1981). Improved quality of life 
is also achieved likely due to reduced dyspnea during exercise, which improves 
performance of activities of daily living. Other benefits include reduction in hematocrit, 
modest neuropsychological improvement, and some improvement in pulmonary 
hemodynamics(Heaton et al,1983;Kvalle,1980;Timms et al,1985 as cited in Shapiro SD,2010). 
Hypoxemia which is defined as a PaO2 of <55 mmHg or oxygen saturation of ˂90%. For 
those whose resting arterial Po2 is between 56 and 59 mmHg, long-term oxygen therapy is 
indicated if they demonstrate erythrocytosis (hematocrit ≥ 55%) or evidence of cor 
pulmonale. Stable ambulatory patients should meet these criteria after being on an optimal 
treatment regimen for at least 30 days (Petty, 1990;Petty & Snider,1988;Tiep,1990 as cited in 
Shapiro SD,2010). Exercise-induced hypoxemia is also an accepted indication for 
supplemental oxygen because it improves exercise performance (Cotes & 
Gilson,1956;Woodcock et al,1981 as cited in Shapiro SD,2010). Supplementary oxygen 
during air travel is recommended for only those individuals whose in-flight PaO2 is 
expected to fall below 50 mmHg since all commercial airline cabins are not always 
pressurized to sea level(Gong,1984;Schwartz et al,1984 as cited in Shapiro SD,2010). Patients 
with major bullous disease run a high risk of life-threatening pneumothorax and hence, 
probably should not fly. Studies have failed to show any benefit arising from nocturnal 
oxygen supplementation targeted at correcting hypoxemic episodes during sleep (Chaouat 
et al,1999,2001; Zanchet & Viegas,2006 as cited in Shapiro SD,2010). 
The continuous-flow nasal cannula is the standard means of oxygen delivery for stable 
hypoxemic patients. The cannula is simple, reliable, and generally well tolerated. Each liter 
of oxygen flow adds 3-4% to the fraction of inspired oxygen (FiO2). Oxygen-conserving 
devices function by delivering all of the oxygen during early inhalation. Three distinct 
oxygen-conserving devices are available, and they include reservoir cannulas, demand-
pulse delivery devices, and transtracheal oxygen delivery. 
ii. Nutrition: 
Patients with advanced COPD and a predominance of emphysema often experience 
progressive weight loss. The weight loss is multifactorial including a 15% to 25% increase in 
resting energy expenditure from elevated work of breathing and increased circulatory 
inflammatory cytokines, higher energy cost of daily activities and a reduced caloric 
intake(Barnes,2009;Di Francia et al,1994 as cited in Shapiro SD,2010). This leads to reduced 
muscle strength including weakness of respiratory muscles thus worsening the dyspnea. 
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Improved nutrition can restore respiratory and general muscle strength and endurance 
(Wilson,1986,Whittaker et al,1990 as cited in Shapiro SD,2010). 
iii. Pulmonary Rehabilitation: 
Comprehensive pulmonary rehabilitation has been shown to improve exercise capacity, 
improve independence quality of life, decrease dyspnea, and decrease health care utilization 
and it may also reduce mortality (Celli et al.,1995 as cited in Shapiro SD,2010). Although 
airflow obstruction ( FEV1) is not improved, the effects of rehabilitation on health status 
(“quality of life”) are generally much greater than seen with pharmacologic treatments 
(Finnerty et al,2001 as cited in Shapiro SD,2010). Pulmonary rehabilitation should be 
considered as an addition to medication therapy for symptomatic patients who have GOLD 
Stage II, III, or IV COPD. 
Pulmonary rehabilitation program usually requires a team approach, including physicians, 
nurses, dietitians, respiratory therapists, exercise physiologists, physical therapists, 
occupational therapists, recreational therapists, cardiorespiratory technicians, pharmacists, 
and psychosocial professionals. This multidisciplinary approach emphasizes on patient and 
family education, smoking cessation, medical management (including oxygen and 
immunization), respiratory and chest physiotherapy, physical therapy with 
bronchopulmonary hygiene, exercise, and vocational rehabilitation and psychosocial support. 
Exercise conditioning is the single most important aspect of rehabilitation and comprises of 
aerobic lower extremity endurance exercises and upper extremity exercise training to 
improve dyspnea and allow increased activities of daily life(ATS,1987). Breathing retraining 
techniques (eg, diaphragmatic and pursed-lip breathing) may improve the ventilatory 
pattern and may prevent dynamic airway compression (Celli,1991;Lotters,2002 as cited in 
Shapiro SD,2010). 
11.2.6 Treatment of respiratory failure 
i. Chronic Ventilatory Failure  - Intermittent Noninvasive Ventilation : 
The use of noninvasive mechanical ventilators is based on the concept that, in patients with 
severe COPD, the respiratory muscles are at the fatigue threshold. Resting the muscles 
provides time for “recovery” and prevents small increases in respiratory requirements from 
precipitating fatigue and perhaps acute respiratory failure. Due to lack of evidence of 
clinical benefit in several studies, the routine use of this form of support for COPD patients 
is not recommended at present(GOLD,2006). 
ii. Altering Ventilatory Control  
a. Almitrine bismesylate - a peripheral chemoreceptor agonist, significantly improves 
resting room air arterial pO2 in about 80% of stable COPD patients mainly from 
improved ventilation-perfusion relationships because almitrine enhances hypoxic 
pulmonary vasoconstriction by way of sympathetic efferent pathways(Bury et 
al.,1989;Romaldini et al.,1983;Weitzenblum et al.,1991 as cited in Shapiro SD,2010). 
Further evidence is needed in its support before it can be recommended for regular 
use in COPD (GOLD,2006). 
b. Analeptic agents: The benefit of the analeptic agents, like acetazolamide, which 
stimulates respiration by acidifying plasma and cerebrospinal fluid(Skatruc & 
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Dempsey,1983 as cited in Shapiro SD,2010), and medroxyprogesterone acetate, 
which directly acts on brainstem respiratory neurons, is not established for COPD 
patients. Clinical benefits are not established for these medications and their use to 
stimulate ventilation in COPD is not recommended(GOLD,2006). 
11.2.7 Surgical intervention 
i. Lung Volume Reduction Surgery: 
Various surgical approaches to improve symptoms and restore function in patients with 
emphysema have been described. Dr. Otto Brantigan pioneered resectional surgery in 1950s, 
but it was Cooper et al’s work showing remarkable improvement in physical measures and 
quality of life measures in patients of COPD who underwent lung volume reduction 
surgery, generated tremendous interest in the procedure and led eventually to the National 
Emphysema Treatment Trial (NETT,1999). The NETT study found a substantial reduction in 
mortality and improvements in HRQOL and exercise capacity as a result of lung volume 
reduction surgery (LVRS) in properly selected patients(Pinto-Plata et al.,2007 as cited in 
Shapiro SD,2010). Caution is recommended in proper selection of patients as individuals 
with an FEV1 less than 20% predicted and either homogenous disease or a diffusion capacity 
of less than 20% predicted were at very high risk for mortality if treated surgically. 
ii. Bullectomy: 
Removal of giant bullae has been a standard approach in selected patients for many years. 
Giant bullae may compress adjacent lung tissue, reducing the blood flow and ventilation to 
the relatively healthy lung. Giant bullectomy can produce subjective and objective 
improvement in selected patients, ie, those who have bullae that occupy at least 30%—and 
preferably 50%—of the hemithorax that compress adjacent lung, with an FEV1 of less than 
50% of predicted and relatively preserved lung function otherwise(Kinnear & 
Tattersfield,1990;Nickoladze,1992 as cited in Shapiro SD,2010). 
iii. Lung transplantation: 
Despite multiple difficulties and obstacles, single-lung transplant has become most common 
procedure of choice when transplantation is performed for emphysema. Available data 
suggest that lung transplantation offers improved function and HRQOL to patients with 
advanced COPD, but it is not clear that it offers any survival benefit(Marulli & 
Rea,2008;Stavem,2006 as cited in Shapiro SD,2010). Worldwide, COPD is the most common 
reason for lung transplantation. Current guidelines by the International Society of Heart and 
Lung Transplantation recommends referring A1PI individuals with COPD for 
transplantation in a scenario with the BODE index greater than 5, post-bronchodilator FEV1 
<25 percent of predicted, resting hypoxemia(PaO2 <55 to 60 mmHg), hypercapnia, 
secondary pulmonary hypertension or accelerated decline in FEV1 (Orens et al.,2006 as cited 
in Shapiro SD,2010). 
11.2.8 Management of acute exacerbations of COPD (AECOPD) 
GOLD and WHO defines an exacerbation of COPD as an acute increase in symptoms 
beyond normal day-to-day variation which includes worsening of cough, increase in 
phlegm production, change in phlegm quality, and increase in dyspnea(GOLD,2006). 
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Variable decrease in pulmonary function, and tachypnea are typical in acute exacerbations 
however, severe cases can lead to respiratory failure and death. Higher exacerbation 
frequency is associated with more loss of FEV1, impairment in quality of life and increase in 
dyspnea with time. 
AECOPDs occur in clusters and patients with an AECOPD were at an increased risk of 
another attack in the 8 weeks following their initial episode(Hurst et al.,2009 as cited in 
Shapiro SD,2010). Viral and bacterial infections and environmental pollutants incite most of 
the acute exacerbations. The single best predictor of exacerbations was a history of 
exacerbations. Other predictors of frequent exacerbations were chronic cough and phlegm 
production, episodic wheezing, pneumonia, active smoking, exertional dyspnoea, lower 
lung function, advanced age, duration of COPD, history of antibiotic therapy, COPD-related 
hospitalization within the previous year  and having one or more comorbidities (eg, 
ischemic heart disease, chronic heart failure, diabetes mellitus or gastroesophageal 
reflux)(Foreman et al.,2007 as cited in Shapiro SD,2010). Important differential diagnosis are 
heart failure, pulmonary thromboembolism, and pneumonia. 
AECOPDs are a major reason for hospital admission for failure of outpatient treatment, 
marked increase in dyspnea, altered mental status, and increase in hypoxemia or 
hypercapnia and respiratory acidosis. Mild episodes may be managed as out-patient. 
Supplemental oxygen is a critical component of acute therapy. It should target an arterial 
oxygen tension (PaO2) of 60 to 70 mmHg(GOLD,2006). If the episode is severe, the patient 
may require ventilatory support in the form of either noninvasive or invasive positive-
pressure ventilation(GOLD,2006). A Cochrane review showed NIPPV reduces mortality, 
avoids endotracheal intubation, and decreased treatment failure(Lightowler et al.,2003 as 
cited in Shapiro SD,2010). 
Pharmacological treatment of COPD includes bronchodilators, antibiotics, and steroids. 
Short-acting bronchodilators are the mainstay of therapy. Oral or parenteral steroids are 
indicated in the treatment of AECOPD and have been shown to shorten recovery time and 
improve outcome and reduce hospital stay. Most exacerbations are treated with full dose 
therapy (eg, prednisone 30 to 40 mg daily) for 7 to 10 days. Antibiotics have been shown to 
provide benefit in patients who present with dyspnea, increased purulence, and increased 
volume of sputum(Fagon et al,1990; Iyer & Murphy,2009 as cited in Shapiro SD,2010). 
12. Prognosis and follow-up 
Several parameters correlate with prognosis in COPD, including forced expiratory volume 
in 1 second (FEV1), diffusion capacity for carbon monoxide (DLCO), blood gas 
measurements, body mass index (BMI), exercise capacity, clinical status and radiographic 
findings on CT scan. A widely used simple prognostication tool is the BODE index, which is 
based on the BMI, obstruction (FEV1), dyspnea (using Medical Research Council Dyspnea 
Scale), and exercise capacity (ie, 6-minute walk distance). 
The 6-min walk test (6MWT) remains the most popular test for the evaluation of exercise 
tolerance in COPD patients. It is simple and well standardised, but its interpretation criteria 
remain controversial. A distance of <361m also predicted mortality in patients with FEV1, 
50% predicted. The 6MWT is currently used to evaluate the impact of treatment. The 
classical 54 m is defined as the minimal significant difference to detect benefit of treatment 
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(Redelmeir et al.,1997 as cited in Shapiro SD,2010). The shuttle walk test offers the 
advantages of being perfectly standardized and highly related to peak oxygen consumption. 
Health status is mostly impaired by exacerbations on the one hand and dyspnoea on the 
other, with its negative effect on daily activity. Some extrapulmonary parameters are also 
correlated with measures of daily activity, independent of GOLD stage and BODE score; 
they include left cardiac dysfunction (as assessed by levels of B-type natriuretic peptide and 
echocardiography) and systemic inflammation (C-reactive protein levels) (Watz et al.,2008 
as cited in Shapiro SD,2010). Frequent exacerbations have a negative long-term impact on 
the BODE index, a well known prognostic factor in COPD, and are not purely respiratory 
episodes but associated with systemic inflammation. 
13. Recent advances 
COPD is an area of intensive research, reporting important advances in the understanding 
of and care for the disease. Evidence from recent epidemiological studies have questioned 
the diagnostic value of the GOLD criteria of fixed FEV1/FVC threshold of 0.7 defining 
airflow limitation. These studies have demonstrated high false-negative rate in young 
subjects at risk and the false-positive rate in older patients(Cerveri et al.,2008;Hansen et 
al.,2007 as cited in Bourdin A,2009). The lower limit of normal(LLN) as recommended by 
American Thoracic Society(ATS) and European Respiratory Society(ERS) seems to be much 
more reliable for defining obstruction, particularly for screening purposes(Swanney et 
al.,2008 as cited in ATS,2010). The criteria of reversibility of airflow obstruction to 
differentiate COPD from asthma has come under question based on wide range of 
reversibility demonstrated in UPLIFT trial (Tashkin et al.,2008).  
Some consider COPD as a component of a broader syndrome that was called ‘‘chronic 
systemic inflammatory syndrome’’. Patients are diagnosed with this syndrome if they have 
three or more components of the following: age  >40 yrs, smoking history >10 pack-yrs, 
symptoms and abnormal lung function compatible with COPD, chronic heart failure, 
metabolic syndrome and increased CRP(Fabbri & Rabe,2007 as cited in Bourdin A,2009). 
New evidence has enhanced the understanding of oxidative stress, injury and protective 
antioxidants such as the glutathione system and the haemoxygenase(HO)-1 pathway. 
Reduced HO-1 expression has been described in macrophages from lung tissue and 
bronchoalveolar lavage (BAL) of smokers with COPD(Maestrelli et al.,2003;Slebos et al.,2004 
as cited in Bourdin A,2009).Moreover, the subtle molecular regulation of HO-1 and its key 
protein regulators, such as Nrf2, Bach1 and Keap1, is modified in COPD. Nrf2 protein level 
is significantly decreased in whole lung tissue and alveolar macrophages and conversely, 
Bach1 and Keap1 levels were increased in patients with emphysema (Goven et al.,2008 as 
cited in Bourdin A,2009). 
A specific antigen reaction is a hypothesis put forward in order to better understand COPD 
progression; T-cells(both CD4 & CD8) may play a role in this possible B-cell mediated 
response. Leptin has been described as a potential regulator of lymphocyte lifespan within 
the airways of COPD patients(Bruno et al.,2005). The production of RANTES (regulated 
upon activation, normal T-cell expressed and secreted) is increased, as shown in the sputum 
of patients with COPD. Regulatory T-cells (Tregs) are special T-lymphocytes that are 
important for preventing autoimmune reactions by inhibiting T-cell responses (Baraldo & 
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Saetta,2008 as cited in Bourdin A,2009). The best described population of Treg is CD4+, and 
expresses CD25 and a transcription factor FOXP3.  
Scores used in clinical practice to assess health status have been modified to be useful in 
primary care setting. The simplified version of the original BODE index, BOD score and a 
new index called ADO(age, dyspnoea and airflow obstruction) have been studied and found 
to have similar accuracy for risk prediction(Puhan et al.,2009 as cited in Bourdin A,2009). 
Thoracic gas compression during forced expiration is a major event in COPD and a new 
index of gas compression defined as (NFEV1-FEV1)/NFEV1 (in percent) was demonstrated 
to be higher at baseline in COPD (32%) than in controls (10%) and it decreased after 
albuterol only in COPD patients. Shuttle walk test for exercise testing, negative expiratory 
pressure(NEP) method and forced oscillation technique(FOT) to measure expiratory flow 
limitation(EFL), single-breath nitrogen washout test(SBN2) for small airway involvement, 
inspiratory muscle endurance(IME) for monitoring respiratory muscle training, 
diaphragmatic electromyogram(EMG) for neural respiratory drive, etc include some of the 
modalities to assess clinical function, response to treatment and some for purely research 
evaluations. 
Newer imaging techniques have recently allowed for the possibility of evaluating 
pulmonary function as well as anatomy. Although helical CT and HRCT have become the 
cornerstone of pulmonary imaging, newer modalities such as PET and MRI may soon 
become critical components in the arsenal of tests used to evaluate pulmonary disease. 
Newer axial CT is as accurate as fiberoptic bronchoscopy (FOB) and virtual bronchoscopy 
(VB), or CT bronchography, has received considerable attention  and excellent internal 
images of the tracheobronchial tree can be generated to the level of the 4th-5th generation 
bronchi. 
Increasing evidence in support of therapy with phosphodiesterase-4 inhibitors, antioxidants 
and augmentation therapy with A1PI in deficient individuals, seem promising. 
Nonrespiratory treatments of co-morbidities with medications such as proton pump 
inhibitors, angiotensin-converting enzyme inhibitors, and statins show promise in the 
management of COPD. Bronchoscopic lung volume reduction (bLVR) is being developed to 
collapse areas of emphysematous lung in hopes of having the same effect on respiratory 
function as LVRS, but without the morbidity and mortality of surgery. Safety and 
effectiveness of minimally invasive approaches like video-assisted thoracoscopy for the 
treatment of giant bullae is under evaluation. 
14. Summary 
 Chronic obstructive pulmonary disease is a common condition with a high morbidity 
and mortality.  
 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as a 
preventable and treatable disease characterized by progressive permanent airflow 
limitation that is not fully reversible. The airflow limitation is associated with an 
abnormal inflammatory response on exposure to noxious particles or gases particularly 
cigarette smoking. 
 There is substantial overlap and co-existence of emphysema, chronic bronchitis, and 
asthma. Injury from smoking excites inflammation, which leads to cellular and 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
150 
extracellular matrix injury which heals with incomplete and disorganized repair 
mechanisms ultimately leading to permanent progressive airflow obstruction. 
Deficiency of anti-protease deficiency makes individuals particularly susceptible to this 
pathologic process with earlier and more severe disease presentation. 
 Patients with COPD present late with chronic respiratory symptoms and majority of 
early stage is asymptomatic and hence needs a high index of suspicion for diagnosis. 
Some patients present with an acute exacerbation.  
 Pulmonary function tests reveal airflow obstruction (ie, a forced expiratory volume in 
one second [FEV1]/forced vital capacity [FVC] ratio less than 0.70) which is 
incompletely reversible. 
 The GOLD staging system is based on spirometry and is well recognized and 
commonly used as a guide for management. It has been criticized for underestimating 
the importance of the extrapulmonary effects of COPD in predicting outcome, which is 
addressed by the BODE index. 
 Cessation of smoking is a central point in treatment of COPD. A short-acting inhaled 
bronchodilator for use on as-needed basis is a reasonable initiation therapy for early 
stage disease(StageIA). Addition of a long-acting inhaled bronchodilator and/or 
glucocorticoid should be considered to improve symptoms, improve lung function, and 
reduce the frequency of exacerbations in Stage IB disease and onwards.  
 Pulmonary rehabilitation is recommended to improve symptoms, exercise capacity, and 
quality of life. Long-term oxygen therapy is indicated in COPD patients who have 
chronic hypoxemia. 
 All patients with COPD should be advised to quit smoking, educated about COPD, and 
influenza/pneumococcal vaccines advised as recommended.  
 Patients who continue to have significant symptoms despite the above interventions 
may be candidates for surgical therapy. 
 Extensive research is ongoing in various aspects of understanding etiopathogenesis and 
treatment options for COPD. 
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